Patents by Inventor Phillip Sharp
Phillip Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110244568Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: October 6, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110244446Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: October 6, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110097329Abstract: The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors.Type: ApplicationFiled: June 24, 2010Publication date: April 28, 2011Applicant: Massachusetts Institute of TechnologyInventors: Paul Chang, Sejal Vyas, Anthony Leung, Phillip A. Sharp
-
Publication number: 20110097328Abstract: The invention provides methods for increasing the activity of an inhibitory RNA (RNAi) in a subject requiring administering one or more poly-ADP-ribose polymerase (PARP) inhibitors and/or one or more PARG activators to the subject. The invention also provides methods for increasing the activity of an inhibitory RNA in a cell or cell population requiring contacting a cell or cell population with one or more PARP inhibitors and/or one or more PARG activators. The invention further provides compositions and kits containing one or more PARP inhibitors and/or one or more PARG activators.Type: ApplicationFiled: June 23, 2010Publication date: April 28, 2011Applicant: Massachusetts Institute of TechnologyInventors: Paul Chang, Anthony Leung, Phillip A. Sharp
-
Patent number: 7763446Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: December 10, 2008Date of Patent: July 27, 2010Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20090186843Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: July 23, 2009Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20090100535Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: ApplicationFiled: December 10, 2008Publication date: April 16, 2009Applicant: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Patent number: 7485441Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: March 7, 2006Date of Patent: February 3, 2009Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20080132461Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: June 5, 2008Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung derInventors: Thomas Tuschi, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20070295870Abstract: A workstation support assembly comprises a support assembly, a post assembly rotationally supported by the support assembly and including a post member, a computer monitor support assembly operably coupled for rotation with a first end of the post member, and a keyboard support assembly operably coupled for rotation with a second end of the post member, wherein rotation of the keyboard support assembly forces rotation of the post member and the monitor support assembly, and wherein rotation of the monitor support assembly does not force the rotation of the keyboard support assembly.Type: ApplicationFiled: June 12, 2007Publication date: December 27, 2007Inventors: Erik Peterson, Dan Tatman, Matthew Adams, Aaron Henningsbaard, Matthew Inouye, Johathan Kaplan, Branko Lukic, Phillip Sharp, Paul Siberschatz, Altay Sendil
-
Publication number: 20070150973Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: ApplicationFiled: March 7, 2006Publication date: June 28, 2007Inventors: Joel Pomerantz, Phillip Sharp, Carl Pabo
-
Publication number: 20070003963Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene finction. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: June 26, 2006Publication date: January 4, 2007Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip Zamore, Phillip Sharp, David Bartel
-
Publication number: 20070003960Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: June 26, 2006Publication date: January 4, 2007Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip Zamore, Phillip Sharp, David Bartel
-
Publication number: 20070003961Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: June 26, 2006Publication date: January 4, 2007Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip Zamore, Phillip Sharp, David Bartel
-
Publication number: 20070003962Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: June 26, 2006Publication date: January 4, 2007Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderug der Wissenschaften E. V.Inventors: Thomas Tuschl, Phillip Zamore, Phillip Sharp, David Bartel
-
Publication number: 20060063709Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: March 23, 2006Inventors: David Baltimore, Ranjan Sen, Phillip Sharp, Harinder Singh, Louis Staudt, Jonathan LeBowitz, Albert Baldwin, Roger Clerc, Lynn Corcoran, Patrick Baeuerle, Michael Lenardo, Chen-Ming Fan, Thomas Maniatis
-
Patent number: 7008780Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: May 10, 2001Date of Patent: March 7, 2006Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20050266552Abstract: The present invention provides reagents such as cells, cell lines, and vectors, that can be used to identify mammalian genes whose expression products (RNA or protein) play a role in RNA interference (RNAi) and/or to identify chemical modulators of RNAi, or for other purposes. The invention further provides a variety of methods for identifying such genes or modulators. In particular, the invention provides a mammalian cell comprising a nucleic acid that encodes a selectable marker and one or more nucleic acid templates for transcription of an RNAi-inducing agent integrated into the genome of the cell, wherein the RNAi-inducing agent reduces expression of the marker and is not naturally found in the cell. Additional cells and cell lines comprising nucleic acids that encode one or more additional markers are also provided. According to certain of the inventive methods cells such as these are mutagenized, transfected or infected with a library of genetic suppressor elements, or contacted with a test compound.Type: ApplicationFiled: December 5, 2004Publication date: December 1, 2005Inventors: John Doench, Derek Dykxhoorn, Carl Novina, Phillip Sharp
-
Publication number: 20040248296Abstract: The present invention provides siRNA methods and compositions for inhibiting HIV infection and/or replication, as well as systems for identifying effective siRNAs for inhibiting HIV and systems for studying HIV infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of an infectious agent; for example, by using siRNAs to inhibit host cell gene expression.Type: ApplicationFiled: March 20, 2003Publication date: December 9, 2004Inventors: Paul J. Beresford, Judy Lieberman, Michael F. Murray, Carl D. Novina, Phillip A. Sharp
-
Publication number: 20040214757Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: October 28, 2004Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis